<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39339194</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1999-4923</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>31</Day></PubDate></JournalIssue><Title>Pharmaceutics</Title><ISOAbbreviation>Pharmaceutics</ISOAbbreviation></Journal><ArticleTitle>Development of a Formulation and In Vitro Evaluation of a Pulmonary Drug Delivery System for a Novel Janus Kinase (JAK) Inhibitor, CPL409116.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1157</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pharmaceutics16091157</ELocationID><Abstract><AbstractText>The pursuit of targeted therapies for cytokine-dependent diseases has led to the discovery of Janus kinase (JAK) inhibitors, a promising class of drugs. Among them, CPL409116, a selective dual JAK and rho-associated protein kinase inhibitor (ROCK), has demonstrated potential for treating conditions such as pulmonary fibrosis exacerbated by the COVID-19 pandemic. This study investigated the feasibility of delivering CPL409116 via inhalation, with the aim of minimizing the systemic adverse effects associated with oral administration. Two micronization methods, jet milling and spray drying, were assessed for CPL409116, with spray drying chosen for its ability to produce an amorphous form of the compound. Moreover, parameters such as the mixing energy, drug load, and force control agent significantly influenced the fine particle fraction (FPF), a critical parameter for pulmonary drug delivery. This study provides insights into optimizing the formulation parameters to enhance the delivery efficiency of CPL409116 to the lungs, offering potential for improved therapeutic outcomes in cytokine-dependent pulmonary diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rzewińska</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4809-6377</Identifier><AffiliationInfo><Affiliation>Finished Dosage Forms Department, Research and Development Center, Celon Pharma S.A., Marymoncka 15, 05-052 Kazuń Nowy, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Drug Technology and Pharmaceutical Biotechnology, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02-097 Warszawa, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szlęk</LastName><ForeName>Jakub</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1537-9650</Identifier><AffiliationInfo><Affiliation>Chair and Department of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dąbrowski</LastName><ForeName>Damian</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Chair of Analytical Chemistry, Faculty of Chemistry, Warsaw University of Technology, Noakowskiego 3, 00-664 Warszawa, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juszczyk</LastName><ForeName>Ewelina</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-5629-5635</Identifier><AffiliationInfo><Affiliation>Finished Dosage Forms Department, Research and Development Center, Celon Pharma S.A., Marymoncka 15, 05-052 Kazuń Nowy, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mróz</LastName><ForeName>Katarzyna</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Finished Dosage Forms Department, Research and Development Center, Celon Pharma S.A., Marymoncka 15, 05-052 Kazuń Nowy, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Räikkönen</LastName><ForeName>Heikki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Faculty of Pharmacy, University of Helsinki, Viikinkaari 5, 00014 Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siven</LastName><ForeName>Mia</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2586-1117</Identifier><AffiliationInfo><Affiliation>Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, 00014 Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helsinki Institute of Sustainability Science HELSUS, University of Helsinki, 00014 Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wieczorek</LastName><ForeName>Maciej</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research and Development Center, Celon Pharma S.A., Marymoncka 15, 05-052 Kazuń Nowy, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorożyński</LastName><ForeName>Przemysław</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-6835-2916</Identifier><AffiliationInfo><Affiliation>Department of Drug Technology and Pharmaceutical Biotechnology, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02-097 Warszawa, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Inorganic and Analytical Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>POIR.01.01.01-00-0454/20</GrantID><Agency>National Centre for Research and Development</Agency><Country /></Grant><Grant><GrantID>778051</GrantID><Agency>European Union's Horizon 2020 Research and Innovation program under the Marie Skłodow-ska-Curie</Agency><Country /></Grant><Grant><GrantID>POIR.04.02.00-00-D023/20</GrantID><Agency>Smart Growth Operational Programme POIR 4.2</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceutics</MedlineTA><NlmUniqueID>101534003</NlmUniqueID><ISSNLinking>1999-4923</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Janus kinase (JAK) inhibitor</Keyword><Keyword MajorTopicYN="N">jet milling (JM)</Keyword><Keyword MajorTopicYN="N">micronization</Keyword><Keyword MajorTopicYN="N">pulmonary drug delivery</Keyword><Keyword MajorTopicYN="N">spray drying (SD)</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339194</ArticleId><ArticleId IdType="pmc">PMC11435004</ArticleId><ArticleId IdType="doi">10.3390/pharmaceutics16091157</ArticleId><ArticleId IdType="pii">pharmaceutics16091157</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>O’Shea J.J., Schwartz D.M., Villarino A.V., Gadina M., McInnes I.B., Laurence A. The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention. Annu. Rev. Med. 2015;66:311–328. doi: 10.1146/annurev-med-051113-024537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-051113-024537</ArticleId><ArticleId IdType="pmc">PMC5634336</ArticleId><ArticleId IdType="pubmed">25587654</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoreschi K., Laurence A., O’Shea J.J. Janus Kinases in Immune Cell Signaling. Immunol. Rev. 2009;228:273–287. doi: 10.1111/j.1600-065X.2008.00754.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2008.00754.x</ArticleId><ArticleId IdType="pmc">PMC2782696</ArticleId><ArticleId IdType="pubmed">19290934</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips R.L., Wang Y., Cheon H.J., Kanno Y., Gadina M., Sartorelli V., Horvath C.M., Darnell J.E., Stark G.R., O’Shea J.J. The JAK-STAT Pathway at 30: Much Learned, Much More to Do. Cell. 2022;185:3857–3876. doi: 10.1016/j.cell.2022.09.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.09.023</ArticleId><ArticleId IdType="pmc">PMC9815833</ArticleId><ArticleId IdType="pubmed">36240739</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz D.M., Kanno Y., Villarino A., Ward M., Gadina M., O’Shea J.J. JAK Inhibition as a Therapeutic Strategy for Immune and Inflammatory Diseases.  [(accessed on 2 July 2024)].  Available online:  https://sci-hub.se/10.1038/nrd.2017.201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2017.201</ArticleId><ArticleId IdType="doi">10.1038/nrd.2017.201</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese L.H., Rose-John S. IL-6 Biology: Implications for Clinical Targeting in Rheumatic Disease. Nat. Rev. Rheumatol. 2014;10:720–727. doi: 10.1038/nrrheum.2014.127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2014.127</ArticleId><ArticleId IdType="pubmed">25136784</ArticleId></ArticleIdList></Reference><Reference><Citation>Feagan B.G., Sandborn W.J., Gasink C., Jacobstein D., Lang Y., Friedman J.R., Blank M.A., Johanns J., Gao L.-L., Miao Y., et al. Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease. N. Engl. J. Med. 2016;375:1946–1960. doi: 10.1056/NEJMoa1602773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1602773</ArticleId><ArticleId IdType="pubmed">27959607</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstovsek S., Mesa R.A., Gotlib J., Levy R.S., Gupta V., DiPersio J.F., Catalano J.V. A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. N. Engl. J. Med. 2012;366:799–807. doi: 10.1056/NEJMoa1110557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1110557</ArticleId><ArticleId IdType="pmc">PMC4822164</ArticleId><ArticleId IdType="pubmed">22375971</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison C., Kiladjian J.-J., Kathrin Al-Ali H., Gisslinger H., Waltzman R., Stalbovskaya V., McQuitty M., Hunter D.S., Levy R., Knoops L., et al. JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. N. Engl. J. Med. 2012;366:787–798. doi: 10.1056/NEJMoa1110556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1110556</ArticleId><ArticleId IdType="pubmed">22375970</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaoka K., Oku K. JAK Inhibitors in Rheumatology. Immunol. Med. 2023;46:143–152. doi: 10.1080/25785826.2023.2172808.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/25785826.2023.2172808</ArticleId><ArticleId IdType="pubmed">36744577</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrera-deGuise C., Serra-Ruiz X., Lastiri E., Borruel N. JAK Inhibitors: A New Dawn for Oral Therapies in Inflammatory Bowel Diseases. Front. Med. 2023;10:1089099. doi: 10.3389/fmed.2023.1089099.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1089099</ArticleId><ArticleId IdType="pmc">PMC10017532</ArticleId><ArticleId IdType="pubmed">36936239</ArticleId></ArticleIdList></Reference><Reference><Citation>King B.A., Craiglow B.G. Janus Kinase Inhibitors for Alopecia Areata. J. Am. Acad. Dermatol. 2023;89:S29–S32. doi: 10.1016/j.jaad.2023.05.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2023.05.049</ArticleId><ArticleId IdType="pubmed">37591562</ArticleId></ArticleIdList></Reference><Reference><Citation>Virtanen A.T., Haikarainen T., Raivola J., Silvennoinen O. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs. 2019;33:15–32. doi: 10.1007/s40259-019-00333-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40259-019-00333-w</ArticleId><ArticleId IdType="pmc">PMC6373396</ArticleId><ArticleId IdType="pubmed">30701418</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke B., Yates M., Adas M., Bechman K., Galloway J. The Safety of JAK-1 Inhibitors. J. Rheumatol. 2021;60:II24–II30. doi: 10.1093/rheumatology/keaa895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa895</ArticleId><ArticleId IdType="pmc">PMC8098103</ArticleId><ArticleId IdType="pubmed">33950230</ArticleId></ArticleIdList></Reference><Reference><Citation>Duong-Quy S., Vo-Pham-Minh T., Tran-Xuan Q., Huynh-Anh T., Vo-Van T., Vu-Tran-Thien Q., Nguyen-Nhu V. Post-COVID-19 Pulmonary Fibrosis: Facts—Challenges and Futures: A Narrative Review. Pulm. Ther. 2023;20:295–307. doi: 10.1007/s41030-023-00226-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s41030-023-00226-y</ArticleId><ArticleId IdType="pmc">PMC10199290</ArticleId><ArticleId IdType="pubmed">37209374</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson M., Rhedin M., Hendrickx R., Berglund S., Piras A., Blomgran P., Cavallin A., Collins M., Dahl G., Dekkak B., et al. Characterization of Selective and Potent JAK1 Inhibitors Intended for the Inhaled Treatment of Asthma. Drug Des. Dev. Ther. 2022;16:2901–2917. doi: 10.2147/DDDT.S354291.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S354291</ArticleId><ArticleId IdType="pmc">PMC9441147</ArticleId><ArticleId IdType="pubmed">36068788</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorino C., Negri S., Spanevello A., Visca D., Scichilone N. Inhalation Therapy Devices for the Treatment of Obstructive Lung Diseases: The History of Inhalers towards the Ideal Inhaler. Eur. J. Intern. Med. 2020;75:15–18. doi: 10.1016/j.ejim.2020.02.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2020.02.023</ArticleId><ArticleId IdType="pubmed">32113944</ArticleId></ArticleIdList></Reference><Reference><Citation>A Study in Healthy Volunteers and Patients with Mild Asthma to Investigate the Safety, Anti-Inflammatory Effect of Inhaled AZD0449.  [(accessed on 5 July 2024)]; Available online:  https://clinicaltrials.gov/study/NCT03766399?term=JAK%20DPI&amp;rank=2.</Citation></Reference><Reference><Citation>Bach J., Eastwood P., González J., Gómez E., Alonso J.A., Fonquerna S., Lozoya E., Orellana A., Maldonado M., Calaf E., et al. Identification of 2-Imidazopyridine and 2-Aminopyridone Purinones as Potent Pan-Janus Kinase (JAK) Inhibitors for the Inhaled Treatment of Respiratory Diseases. J. Med. Chem. 2019;62:9045–9060. doi: 10.1021/acs.jmedchem.9b00533.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.9b00533</ArticleId><ArticleId IdType="pubmed">31609613</ArticleId></ArticleIdList></Reference><Reference><Citation>Dulak-Lis M., Bujak A., Gala K., Banach M., Kędzierska U., Miszkiel J., Hucz-Kalitowska J., Mroczkiewicz M., Stypik B., Szymczak K., et al. A Novel JAK/ROCK Inhibitor, CPL409116, Demonstrates Potent Efficacy in the Mouse Model of Systemic Lupus Erythematosus. J. Pharmacol. Sci. 2021;145:340–348. doi: 10.1016/j.jphs.2021.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jphs.2021.02.002</ArticleId><ArticleId IdType="pubmed">33712286</ArticleId></ArticleIdList></Reference><Reference><Citation>Spahn J.E., Zhang F., Smyth H.D.C. Mixing of Dry Powders for Inhalation: A Review. Int. J. Pharm. 2022;619:121736. doi: 10.1016/j.ijpharm.2022.121736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2022.121736</ArticleId><ArticleId IdType="pubmed">35405281</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebbink G.A., Jaspers M., Peters H.J.W., Dickhoff B.H.J. Recent Developments in Lactose Blend Formulations for Carrier-Based Dry Powder Inhalation. Adv. Drug Deliv. Rev. 2022;189:114527. doi: 10.1016/j.addr.2022.114527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2022.114527</ArticleId><ArticleId IdType="pubmed">36070848</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipiäinen T., Räikkönen H., Kolu A.M., Peltoniemi M., Juppo A. Comparison of Melibiose and Trehalose as Stabilising Excipients for Spray-Dried β-Galactosidase Formulations. Int. J. Pharm. 2018;543:21–28. doi: 10.1016/j.ijpharm.2018.03.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2018.03.035</ArticleId><ArticleId IdType="pubmed">29567196</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., Rudolph V., Weigl B., Earl A. Interparticle Van Der Waals Force in Powder Flowability and Compactibility. Int. J. Pharm. 2004;280:77–93. doi: 10.1016/j.ijpharm.2004.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2004.05.001</ArticleId><ArticleId IdType="pubmed">15265549</ArticleId></ArticleIdList></Reference><Reference><Citation>Thalberg K., Papathanasiou F., Fransson M., Nicholas M. Controlling the Performance of Adhesive Mixtures for Inhalation Using Mixing Energy. Int. J. Pharm. 2021;592:120055. doi: 10.1016/j.ijpharm.2020.120055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2020.120055</ArticleId><ArticleId IdType="pubmed">33176199</ArticleId></ArticleIdList></Reference><Reference><Citation>Shetty N., Cipolla D., Park H., Zhou Q.T. Physical Stability of Dry Powder Inhaler Formulations. Expert Opin. Drug Deliv. 2020;17:77–96. doi: 10.1080/17425247.2020.1702643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17425247.2020.1702643</ArticleId><ArticleId IdType="pmc">PMC6981243</ArticleId><ArticleId IdType="pubmed">31815554</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarara T.E., Miller D.P., Weers A.E., Muliadi A., Tso J., Eliahu A., Weers J.G. Formulation of Dry Powders for Inhalation Comprising High Doses of a Poorly Soluble Hydrophobic Drug. Front. Drug Deliv. 2022;2:862336. doi: 10.3389/fddev.2022.862336.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fddev.2022.862336</ArticleId></ArticleIdList></Reference><Reference><Citation>Elsayed M.M.A., Alfagih I.M., Brockbank K., Aodah A.H., Ali R., Almansour K., Shalash A.O. Critical Attributes of Fine Excipient Materials in Carrier-Based Dry Powder Inhalation Formulations: The Particle Shape and Surface Properties. Int. J. Pharm. 2024;655:123966. doi: 10.1016/j.ijpharm.2024.123966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2024.123966</ArticleId><ArticleId IdType="pubmed">38452834</ArticleId></ArticleIdList></Reference><Reference><Citation>Healy A.M., Amaro M.I., Paluch K.J., Tajber L. Dry Powders for Oral Inhalation Free of Lactose Carrier Particles. Adv. Drug Deliv. Rev. 2014;75:32–52. doi: 10.1016/j.addr.2014.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2014.04.005</ArticleId><ArticleId IdType="pubmed">24735676</ArticleId></ArticleIdList></Reference><Reference><Citation>Chvatal A., Ambrus R., Party P., Katona G., Jójárt-Laczkovich O., Szabó-Révész P., Fattal E., Tsapis N. Formulation and Comparison of Spray Dried Non-Porous and Large Porous Particles Containing Meloxicam for Pulmonary Drug Delivery. Int. J. Pharm. 2019;559:68–75. doi: 10.1016/j.ijpharm.2019.01.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2019.01.034</ArticleId><ArticleId IdType="pubmed">30677482</ArticleId></ArticleIdList></Reference><Reference><Citation>Stegemann S., Faulhammer E., Pinto J.T., Paudel A. Focusing on Powder Processing in Dry Powder Inhalation Product Development, Manufacturing and Performance. Int. J. Pharm. 2022;614:121445. doi: 10.1016/j.ijpharm.2021.121445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2021.121445</ArticleId><ArticleId IdType="pubmed">34998921</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman S.P. Drug Delivery to the Lungs: Challenges and Opportunities. Ther. Deliv. 2017;8:647–661. doi: 10.4155/tde-2017-0037.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/tde-2017-0037</ArticleId><ArticleId IdType="pubmed">28730933</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwok P.C.L., Chan H.K. Pulmonary Drug Delivery. Ther. Deliv. 2013;4:877–878. doi: 10.4155/tde.13.89.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/tde.13.89</ArticleId><ArticleId IdType="pubmed">23919463</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaurasiya B., Zhao Y.Y. Dry Powder for Pulmonary Delivery: A Comprehensive Review. Pharmaceutics. 2021;13:31. doi: 10.3390/pharmaceutics13010031.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics13010031</ArticleId><ArticleId IdType="pmc">PMC7824629</ArticleId><ArticleId IdType="pubmed">33379136</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng X.M., Martin G.P., Marriott C., Pritchard J. The Influence of Carrier Morphology on Drug Delivery by Dry Powder Inhalers. Int. J. Pharm. 2000;200:93–106. doi: 10.1016/S0378-5173(00)00347-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0378-5173(00)00347-1</ArticleId><ArticleId IdType="pubmed">10845690</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Rao Q., Qiu Z., Lin Y., Zhang L., Hu Q., Chen T., Ma Z., Gao H., Luo D., et al. Using Acetone/Water Binary Solvent to Enhance the Stability and Bioavailability of Spray Dried Enzalutamide/HPMC-AS Solid Dispersions. J. Pharm. Sci. 2021;110:1160–1171. doi: 10.1016/j.xphs.2020.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2020.10.010</ArticleId><ArticleId IdType="pubmed">33049259</ArticleId></ArticleIdList></Reference><Reference><Citation>Aulton M., Buckton G.  Aulton’s Pharmaceutics. 2007.  [(accessed on 26 August 2024)]. The Design and Manufacture of Medicines. Available online:  https://shop.elsevier.com/books/aultons-pharmaceutics/taylor/978-0-7020-8154-5.</Citation></Reference><Reference><Citation>Saldanha S., Fernandes B., Ventura J. Spray Drying as an Enabling Technology for Inhalation Drug Delivery. Pharm. Technol. 2021;45:36–40.</Citation></Reference><Reference><Citation>Novakovic D., Peltonen L., Isomäki A., Fraser-Miller S.J., Nielsen L.H., Laaksonen T., Strachan C.J. Surface Stabilization and Dissolution Rate Improvement of Amorphous Compacts with Thin Polymer Coatings: Can We Have It All? Mol. Pharm. 2020;17:1248–1260. doi: 10.1021/acs.molpharmaceut.9b01263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.molpharmaceut.9b01263</ArticleId><ArticleId IdType="pmc">PMC7145361</ArticleId><ArticleId IdType="pubmed">32027513</ArticleId></ArticleIdList></Reference><Reference><Citation>Novakovic D., Isomäki A., Pleunis B., Fraser-Miller S.J., Peltonen L., Laaksonen T., Strachan C.J. Understanding Dissolution and Crystallization with Imaging: A Surface Point of View. Mol. Pharm. 2018;15:5361–5373. doi: 10.1021/acs.molpharmaceut.8b00840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.molpharmaceut.8b00840</ArticleId><ArticleId IdType="pmc">PMC6221374</ArticleId><ArticleId IdType="pubmed">30247922</ArticleId></ArticleIdList></Reference><Reference><Citation>Begat P., Morton D.A.V., Shur J., Kippax P., Staniforth J.N., Price R. The Role of Force Control Agents in High-Dose Dry Powder Inhaler Formulations. J. Pharm. Sci. 2009;98:2770–2783. doi: 10.1002/jps.21629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.21629</ArticleId><ArticleId IdType="pubmed">19067395</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q.T., Qu L., Larson I., Stewart P.J., Morton D.A.V. Improving Aerosolization of Drug Powders by Reducing Powder Intrinsic Cohesion via a Mechanical Dry Coating Approach. Int. J. Pharm. 2010;394:50–59. doi: 10.1016/j.ijpharm.2010.04.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2010.04.032</ArticleId><ArticleId IdType="pubmed">20435112</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumon M., Machida S., Suzuki M., Kusai A., Yonemochi E., Terada K. Application and Mechanism of Inhalation Profile Improvement of DPI Formulations by Mechanofusion with Magnesium Stearate. Chem. Pharm. Bull. 2008;56:617–625. doi: 10.1248/cpb.56.617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/cpb.56.617</ArticleId><ArticleId IdType="pubmed">18451547</ArticleId></ArticleIdList></Reference><Reference><Citation>Young P.M., Wood O., Ooi J., Traini D. The Influence of Drug Loading on Formulation Structure and Aerosol Performance in Carrier Based Dry Powder Inhalers. Int. J. Pharm. 2011;416:129–135. doi: 10.1016/j.ijpharm.2011.06.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2011.06.020</ArticleId><ArticleId IdType="pubmed">21708238</ArticleId></ArticleIdList></Reference><Reference><Citation>Shur J., Price R., Lewis D., Young P.M., Woollam G., Singh D., Edge S. From Single Excipients to Dual Excipient Platforms in Dry Powder Inhaler Products. Int. J. Pharm. 2016;514:374–383. doi: 10.1016/j.ijpharm.2016.05.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2016.05.057</ArticleId><ArticleId IdType="pubmed">27262269</ArticleId></ArticleIdList></Reference><Reference><Citation>Benke E., Farkas Á., Szabó-Révész P., Ambrus R. Development of an Innovative, Carrier-Based Dry Powder Inhalation Formulation Containing Spray-Dried Meloxicam Potassium to Improve the In Vitro and In Silico Aerodynamic Properties. Pharmaceutics. 2020;12:535. doi: 10.3390/pharmaceutics12060535.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics12060535</ArticleId><ArticleId IdType="pmc">PMC7356266</ArticleId><ArticleId IdType="pubmed">32532040</ArticleId></ArticleIdList></Reference><Reference><Citation>Adi H., Larson I., Chiou H., Young P., Traini D., Stewart P. Role of Agglomeration in the Dispersion of Salmeterol Xinafoate from Mixtures for Inhalation with Differing Drug to Fine Lactose Ratios. J. Pharm. Sci. 2008;97:3140–3152. doi: 10.1002/jps.21228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.21228</ArticleId><ArticleId IdType="pubmed">18023007</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones M.D., Hooton J.C., Dawson M.L., Ferrie A.R., Price R. An Investigation into the Dispersion Mechanisms of Ternary Dry Powder Inhaler Formulations by the Quantification of Interparticulate Forces. Pharm. Res. 2008;25:337–348. doi: 10.1007/s11095-007-9467-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-007-9467-1</ArticleId><ArticleId IdType="pubmed">17952568</ArticleId></ArticleIdList></Reference><Reference><Citation>Morin G., Briens L. The Effect of Lubricants on Powder Flowability for Pharmaceutical Application. AAPS PharmSciTech. 2013;14:1158–1168. doi: 10.1208/s12249-013-0007-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12249-013-0007-5</ArticleId><ArticleId IdType="pmc">PMC3755167</ArticleId><ArticleId IdType="pubmed">23897035</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttini F., Brambilla G., Copelli D., Sisti V., Balducci A.G., Bettini R., Pasquali I. Effect of Flow Rate on In Vitro Aerodynamic Performance of NEXThaler in Comparison with Diskus and Turbohaler Dry Powder Inhalers. J. Aerosol Med. Pulm. Drug Deliv. 2016;29:167–178. doi: 10.1089/jamp.2015.1220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jamp.2015.1220</ArticleId><ArticleId IdType="pmc">PMC4841907</ArticleId><ArticleId IdType="pubmed">26355743</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>